Clinical Research Directory
Browse clinical research sites, groups, and studies.
Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia
Sponsor: West China Second University Hospital
Summary
This is a multicenter, randomized, open-label, parallel-controlled, prospective clinical study. It aims to evaluate the efficacy and safety of aerosolized Peginterferon α-2b injection in the treatment of pediatric respiratory syncytial virus pneumonia. The overall study is divided into a screening period, a treatment period, and a follow-up period. Eligible children with respiratory syncytial virus pneumonia will be randomly assigned to the experimental group 1, experimental group 2, and the control group at a ratio of 1:1:1.
Official title: A Phase 2 Multicenter, Randomized, Open-label Study to Evaluate the Pharmacokinetic, Safety and Efficacy of Peginterferon Alfa-2b Injection in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.
Key Details
Gender
All
Age Range
1 Year - 3 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2024-07-17
Completion Date
2026-03-31
Last Updated
2025-03-18
Healthy Volunteers
No
Conditions
Interventions
Peginterferon α-2b injection
Peginterferon α-2b injection, 45 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.
Peginterferon α-2b injection
Peginterferon α-2b injection, 90 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.
symptomatic and supportive treatment
symptomatic and supportive treatment
Locations (2)
Chengdu Women's and Children's Central Hospital
Chengdu, Sichuan, China
West China Second University Hospital of Sichuan University
Chengdu, Sichuan, China